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Summary
Chronic lymphocytic leukemia (CLL) remains incurable; therefore searching for new thera-
peutic strategies in this disease is necessary. An important mechanism of tumor development is 
neoangiogenesis. A potent antiangiogenic factor, bevacizumab (Avastin, AVA), has been poorly 
explored in CLL so far. In the current study we assessed cytotoxic activity of AVA alone or in 
combinations with drugs routinely used in this disease.
Cells isolated from 60 CLL patients were treated with AVA alone or in combination with an-
ti-CD20 monoclonal antibody (MoAb), rituximab (RIT), anti-CD52 MoAb, alemtuzumab 
(ALT), 2-CdA (2-chlorodeoxyadenosine), FA (fludarabine), MAF (mafosfamide) or RAPA 
(rapamycin). Cytotoxicity was assessed by propidium iodide staining. Apoptosis was evaluated 
using annexin-V and TUNEL assays. Additionally, a drop of mitochondrial potential (DYm) 
as well as expression of apoptosis-regulating proteins Bax, Bak, Bid, Bad, Bcl-2, Mcl-2, XIAP, 
FLIP, Akt and Bcl-2-A1 were determined by flow cytometry.
At the dose of 40 μg/ml, after 48 hours of incubation, AVA induced significant cytotoxicity 
against CLL cells. The drug triggered apoptosis, with activation of caspase-3 and -9, but not 
caspase-8, along with a drop of DYm. Incubation with AVA induced significant overexpression 
of proapoptotic Bak and Bad as well as downregulation of antiapoptotic Mcl-2 and Akt prote-
ins. Combination of AVA with RIT, ALT or RAPA significantly increased cytotoxicity when 
compared with the effects of single drugs.
In conclusion, this is the first report showing proapoptotic activity of AVA against CLL cells. 
Combination of AVA with RIT, ALT or RAPA may be a promising therapeutic strategy, which 
requires confirmation in further studies.
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Streszczenie
Przewlekła białaczka limfocytowa (PBL) wciąż pozostaje chorobą nieuleczalną, dlatego 
wysiłki skierowane na opracowanie nowych strategii leczniczych są w pełni uzasadnione. 
Ważnym mechanizmem rozwoju nowotworów jest neoangiogeneza. Znany od kilku lat 
czynnik antyangiogenny, bewacyzumab (avastin - AVA), aktywny w niektórych nowotwo-
rach litych, jest wciąż stosunkowo słabo zbadany w PBL. Celem podjętych badań była oce-
na aktywności cytotoksycznej AVA w odniesieniu do komórek PBL, zarówno po zastoso-
waniu w monoterapii jak i w skojarzeniu z lekami rutynowo stosowanymi w tej chorobie.
Komórki izolowane od 60 chorych na PBL były inkubowane z AVA pojedynczo lub z prze-
ciwciałami monoklonalnymi anty-CD20 (rytuksymab - RIT) i anty-CD52 (alemtuzu-
mab - ALT), a także z kladrybiną (2-chlorodeoxyadenozyna - 2-CdA), fludarabiną (FA), 
mafosfamidem (MAF - aktywny biologicznie metabolit cyklofosfamidu) lub rapamycyną 
(RAPA). Cytotoksyczność badano za pomocą testu z jodkiem propydyny. Apoptozę oce-
niano za pomocą testów z Anneksyną V (Ann-V) oraz TUNEL. Ponadto badano spadek 
potencjału mitochondrialnego (DYm) oraz ekpresję białek regulujących apoptozę (Bax, 
Bak, Bid, Bad, Bcl-2, Mcl-2, XIAP, FLIP, Akt i Bcl-2-A1). Badania te wykonywano tech-
niką cytometrii przepływowej.
W dawce 40 μg/ml, po 48 godzinach inkubacji, AVA indukował znaczącą cytotoksyczność 
w odniesieniu do komórek PBL. Lek ten indukował apoptozę poprzez aktywację kaspaz 
3 i 9, ale nie kaspazy 8; zanotowano przy tym wyraźny spadek DYm. Inkubacja z AVA 
powodowała znamienny wzrost ekspresji Bak i Bad oraz obniżenie ekspresji białek Mcl-2 
i Akt. Skojarzenie AVA z RIT, ALT lub RAPA znamiennie zwiększało cytotoksyczność 
w porównaniu do efektu poszczególnych leków stosowanych pojedynczo.
Podsumowując, jest to pierwsze doniesienie wykazujące proapoptotyczną aktywność AVA 
w odniesieniu do komórek PBL. Skojarzenie AVA z RIT, ALT czy RAPA może być obie-
cującą strategią terapeutyczną, co wymaga jednak potwierdzenia w dalszych badaniach, 
w tym prowadzonych in vivo.
przewlekła białaczka limfocytowa • PBL • angiogeneza • bewacyzumab • apoptoza
Adres autora: Prof. Piotr Smolewski, MD, PhD, Department of Experimental Hematology,  
Medical University of Lodz, Copernicus Memorial Hospital, 2 Ciołkowskiego Street,  
93-510 Łódź, Poland; e-mail:piotr_smolewski@wp.pl
Słowa kluczowe:
Dyskusja:
Wyniki:
Metody:
Wprowadzenie:
IntroductIon
Chronic lymphocytic leukemia (CLL) is one of the most 
frequent hematologic malignancies. Despite the progress 
in CLL treatment, the disease still remains incurable. 
Therefore, it is necessary to search for new therapeutic 
strategies.
Introduction of monoclonal antibodies (MoAbs) anti-
-CD20 (rituximab, RIT) and anti-CD52 (alemtuzu-
mab, ALT) [5, 18] to CLL therapy gave some promise 
for improvement of outcome in this disease. The main 
mechanisms of antineoplastic action are CDC (com-
plement-dependent cytotoxicity) and ADCC (anti-
body-dependent cellular cytotoxicity). Still the main 
drugs active in CLL are purine nucleoside analogu-
es (PNA), including fludarabine (FA) and cladribine 
(2-chlorodeoxyadenosine; 2-CdA). Their cytotoxicity, 
similarly to many other routinely used cytostatics, is 
based mostly on triggering tumor cell apoptosis [19].109 109
Neoangiogenesis is one of the most important mecha-
nisms leading to development of neoplastic diseases, 
including hematologic malignancies. Therefore, inhibi-
tion of this process may have therapeutic potential in 
these disorders. Among clinically potent antiangioge-
nic factors, the best known is humanized MoAb against 
VEGF (vascular endothelial growth factor), bevacizu-
mab (Avastin, AVA) [27]. AVA binds VEGF, leading to 
its inhibition. In turn it blocks vessel proliferation and 
inhibits tumor growth [14]. The drug was approved for 
treatment of metastatic colon cancer and then for the-
rapy of disseminated breast cancer and non-small cell 
lung cancer.
The potential mechanism of antitumor action of AVA is 
ADCC or CDC immunological cytotoxicity, with the sug-
gestion of eventual proapoptotic action. This latter mecha-
nism would be very important, because of the possibility of 
antitumor strategy intensification by combination of AVA 
with other drugs, either cytostatics or other MoAbs.
Antitumor AVA activity in CLL has not been compre-
hensively explored so far, although the problem may be 
of clinical value. Namely, neoangiogenesis is probably 
important in pathogenesis of CLL [16]. Expression of 
VEGF receptors (VEGFRs) on leukemic cells and the 
presence of circulating serum VEGFRs have already been 
reported in this disease. In this study, we performed the 
first reported complex analysis of cytotoxic potential of 
AVA on CLL cells in ex vivo conditions. Cytotoxicity 
and its mechanisms were measured either for AVA alone 
or for its combinations with routinely used cytostatics or 
biological drugs active in CLL or other malignant lym-
phoproliferations.
MaterIal and Methods
The ex vivo studies were performed on peripheral blood 
mononuclear cells (PBMCs) obtained from 55 previo-
usly untreated CLL patients. In this group were 24 wo-
men and 31 men, aged 43-85 years (median 69 years). 
The control group consisted of 18 healthy volunteers.
PBMC isolation
PBMCs were isolated from heparinized blood samples by 
centrifugation in Histopaque-1077 (Sigma Diagnostic, St 
Louis MO, USA) density gradients. A 1:1 (v/v) mixture 
of blood and Hanks’ Balanced Salt Solution (HBSS; Bio-
med, Poland) was layered on top of the Histopaque me-
dia in centrifuge tubes and centrifuged for 30 minutes at 
200xg. The interphase region containing PBMC was col-
lected and then washed twice, in HBSS and RPMI 1640 
medium. Next, the cells were divided; a portion of them 
was resuspended in phosphate buffered saline (PBS; Sig-
ma Aldrich Chemie GmbH, Germany) for the immuno-
phenotypic study. The remaining cells were resuspended 
in RPMI 1640 at a cell density of about 0.5x106 cells/ml, 
and 1000 ml aliquots of cell suspensions were placed into 
24 culture well dishes (Nunc, Denmark).
Cell immunophenotyping 
Immunophenotyping of leukemic cells was perfor-
med routinely in the whole peripheral blood (the “ly-
sed – not washed” method). A routine panel of MoAbs 
(CD3, CD5, CD10, CD11c, CD19, CD23, FMC7, 
IgΚ and Igλ), fluorescein isothiocyanate (FITC), R-
-phycoerythrin (R-PE) or cyanine-5 (Cy5) conjugated 
(all BD Pharmingen, San Diego, CA, USA) was eva-
luated using triple-color flow cytometry. The diagnosis 
was confirmed based on detecting the leukemic CD5+/
CD19+/CD23+ clone. The rate of B-CLL cell popula-
tion ranged from 59% to 98% of peripheral blood whi-
te cells (mean 84.1%). Based on this staining CD5+/
CD19+ B-CLL cells could be distinguished from nor-
mal PBMCs for further multi-color analyses by flow 
cytometry.
PBMc culture desIgn
Drugs
The following sets of cultures were prepared: controls 
containing PBMCs collected before treatment and 
cells treated with the study drugs. There were: AVA 
(Avastin, ROCHE, Switzerland; the drug was kindly 
provided by ROCHE Poland, Sp. z o.o.), RIT (Mab-
thera, ROCHE, Switzerland), ALT (CAMPATH-1H, 
ILEX Oncology, Inc., USA), 2-CdA (Biodrybin, Bio-
ton, Poland), FA (Fludarabine, Bayer-Schering, Ger-
many), MAF (kindly provided by the Department of 
Biochemistry, University of Lodz, Poland) and RAPA 
(Sigma, Aldrich, Denmark) alone. Moreover, combi-
nations of AVA with RIT, ALT, 2-CdA, FA, MAF or 
RAPA were tested.
After a series of preliminary experiments (AVA in 
concentrations from 1 to 100 μg/ml) the dose of AVA 
40 μg/ml was chosen for further studies. That was the 
minimal drug concentration inducing significant cy-
totoxicity compared with the untreated samples after 
48 h of incubation. This action was independent of ad-
ditional usage of complement, healthy control PBMCs 
containing cytotoxic cells, as well as of the presence of 
cross-linking with IgG antibodies.
Doses of other drugs were chosen based on previous 
experience and set at 10 μg/ml for RIT, and 20 μg/ml 
for ALT. 2-CdA was used in a final concentration of 
20 μg/ml, as 10 times lower than in serum in vivo. Mo-
reover, the dose of FA was 20 μg/ml, whereas that of 
MAF and RAPA was 8 μg/ml and 10 μg/ml, respec-
tively.
Culture settings
All cultures were maintained for up to 24 h in RPMI 
1640 medium containing 10% (v/v) heat-inactivated 
fetal calf serum (FCS) and antibiotics (streptomycin 50 
mg/ml, penicillin 50 IU/ml; Life Technologies, Sco-
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tland), at 37°C, 5% CO2, fully humidified. At the 0 h 
time point, after 24 h and 48 h PBMCs were subjec-
ted to a simultaneous assessment of viability, apoptosis 
or protein expression analysis by flow cytometry, using 
standard emission filters: green (FL1) for FITC, oran-
ge FL2 for R-PE and red (FL3) for Cy5.
Moreover, incubation in the presence of secondary IgG 
cross-linking antibody, complement or healthy PBMCs 
was used to potentiate cytotoxicity of AVA. Namely, for 
cross-linking studies the goat anti-human IgG, Fcg frag-
ment specific (Jackson Immuno Research, West Grove, 
USA) secondary antibody was used at a concentration of 
20 μg/ml. The secondary antibody was added 30 minutes 
after application of RIT or CAM. To mimic the CDC 
effect in vitro, additional incubation with complement 
was performed in two separate settings. Thus, for com-
plement-mediated lysis pooled human serum from heal-
thy donors or serum obtained from the examined patient 
was used. Human serum was added to a 5% final con-
centration together with the MoAb. Finally, to mimic 
the in vivo ADCC effect, PBMCs isolated from healthy 
volunteers were added to the examined sample. Patients 
and control cells were mixed in the proportion 1:14.
In all experiments with, cytotoxicity of RIT and ALT 
was tested with addition of secondary IgG cross-linking 
antibody. Calculation of exact cell number in the sample 
before and after incubation was performed using the Z1 
Coulter Particle Counter/Beckman Coulter, when ne-
cessary.
Evaluation of VEGF level and VEGFR expres-
sion
In the series of experiments, the VEGF Human ELISA 
Kit (Lyfe Technologies, Grand Island, NY, USA) was 
used to quantify VEGF in cell culture medium before and 
after incubation with AVA. Similarly, the presence and 
expression of VEGFR on CLL cells was assessed, using 
anti-VEGFR-1 and anti-VEGFR-2 anti-human anti-
bodies (VEGFR2/KRD-APC and VEGFR1/Flt1-PE; 
both R&D systems, UK).
Assessment of drug cytotoxicity
Cytotoxicity (cell viability) was assessed based on propi-
dium iodide (PI) staining. After incubation with drugs, 
cells were washed twice in PBS and then re-suspended in 
0.5 ml of 10 mg/ml PBS/PI solution. After 10 minutes of 
staining (room temperature, in the dark) cell fluorescen-
ce was measured by flow cytometry, using the FL3 (red) 
standard fluorescent filter. The viable cells were defined as 
PI-negative.
Assessment of apoptosis 
and its mechanisms
Apoptosis was evaluated based on annexin V (Ann-V) 
and TUNEL assays. Additionally, activation of caspa-
se-3, -9 and -8, drop of mitochondrial transmembra-
ne potential (DYm) as well as expression of apoptotic/
proliferation regulatory proteins such as Bax, Bak, Bid, 
bad, Bcl-2, Mcl-2, XIAP, FLIP, Akt and A1 were de-
termined.
Assessment of apoptosis by Ann-V assay
The rate of apoptosis was determined by Ann-V assay 
after 24 h of incubation with the drugs. In brief, after 
incubation cells were washed twice with cold PBS and 
then resuspended in 100 ml of binding buffer, conta-
ining 2 ml of FITC conjugated Ann-V and 10 mg/ml of 
PI (Becton-Dickinson, San Jose, CA, USA). Next, the 
samples were incubated for 15 minutes, at room tempe-
rature, in the dark. The fluorescence was measured im-
mediately after staining by flow cytometer using FL1 
(green, Ann-V) and FL3 (red, PI) standard fluorescent 
filters.
Assessment of apoptosis  
by TUNEL assay
Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) is a method for detecting DNA 
fragmentation by labeling the terminal end of nucle-
ic acids.
The APO-DIRECT™ assay (BD Pharmingen, San 
Jose, CA, USA), used in this study, is a single-step me-
thod for labeling DNA breaks with FITC-dUTP, fol-
lowed by flow cytometric analysis. Before fixation in 
ethanol, the cells are fixed in 1% methanol-free para-
formaldehyde, in order to crosslink the DNA fragments 
into the cell and to maximize the number of broken 
DNA ends. In the APO-DIRECT™ assay, TdT cata-
lyzes addition of bromolated deoxyuridine triphospha-
tes (Br-dUTP) to the 3’-hydroxyl (OH) termini of do-
uble- and single-stranded DNA. After incorporation, 
these sites are identified by staining the cells with a 
FITC-labeled anti-BrdU MoAb. The fluorescence was 
measured by flow cytometry using an FL1 filter for de-
tecting the green fluorescence.
Detection of active caspase-3
Active caspase-3 was detected using FITC-conjugated 
monoclonal rabbit anti-active caspase-3 antibody (BD 
Pharmingen, San Diego, CA, USA). After incubation 
cells were fixed and permeabilized using Cytofix/Cy-
topermTM (BD Pharmingen, San Diego, CA, USA) 
solution (20 minutes, on ice), then washed twice and 
resuspended in Perm/WashTM buffer (BD Pharmin-
gen, San Diego, CA, USA). The antibody was added 
in the amount of 60 ml per 300 ml of cell suspension 
(30 minutes incubation, at room temperature). The 
fluorescence was measured directly after staining and 
washing in Perm/WashTM buffer by flow cytometry 
using an FL1 filter for detecting the green fluorescence 
of anti-active caspase-3 antibody.111 111
Assessment of caspase-8 
and caspase-9 activation
Synthetic fluorochrome labeled fluoromethyl ketone 
peptides that are cell permeant and bind to the active 
catalytic site of caspase proteases were developed by 
Immunochemistry Technologies LLC (Bloomington, 
MN, USA). Commercially available FAM-LETD-
-FMK FLICA™ Caspase 8 Assay Kit and FAM-
-LEHD-FMK Reagent-9 FLICA™ Caspase 9 Assay 
Kit were used for assessment of caspase-8 and caspa-
se-9 activation. According to the insert protocol it was 
initially prepared as a 150x concentrated solution in 
dimethylsulfoxide (DMSO; SIGMA Aldrich, USA). 
Aliquots were stored at -20°C, protected from light. 
Directly before use, they were diluted in PBS (1:5), and 
then added to 300 ml of culture to obtain a 10 mM 
concentration of FAM-LETD-FMK (caspase-8 de-
tection) or FAM-LEDH-FMK (caspase-9 detection), 
respectively, for the final hour of incubation. Cultures 
were terminated by washing the cells twice (5 minu-
tes, 140xg) with the “wash buffer” (component of both 
kits). After centrifugation, the pellets were resuspen-
ded in 1 ml of wash buffer and the samples were pla-
ced on ice. Cell green fluorescence derived from FAM-
-LETD-FMK or FAM-LEDH-FMK was measured 
during the next 15 minutes by flow cytometry.
Collapse of ΔΨm assessment
Dissipation of ΔΨm occurs early during apoptosis 
and is often considered as a marker of apoptosis ac-
tivated by the mitochondrial pathway. As a probe of 
ΔΨm we used MitoTracker Red 580 dye (Molecular 
Probes, Eugene, Oregon, USA), which accumulates in 
active mitochondria of living cells. The stock solution 
of MitoTracker Red (1 mM) was diluted to a working 
concentration of 50 nM by adding to the growth cultu-
re medium (20 minutes incubation, at room tempera-
ture). The drop of ΔΨm was visualized by the decrease 
in red fluorescence of the dye, and detected by flow cy-
tometry using an FL3 fluorescence filter.
Expression of apoptosis-regulating 
proteins
For assessment of the cellular expression of proteins 
involved in mechanisms of apoptosis regulation, cells 
were fixed with 1% methanol-free paraformaldehyde 
and permeabilized with 0.1% polysorbate 20 (Twe-
en-20) in PBS (Amersham Biosciences, Freiburg, Ger-
many). These were proteins acting on different levels of 
apoptotic pathways: promoters of apoptosis from the 
Bcl-2 protein family (Bax, Bak, Bid, Bad), and apop-
tosis inhibitors (Bcl-2, Mcl-1, XIAP and FLIP). An-
ti-human Bax primary rabbit Ab (DAKO, Glostrup, 
Denmark) was used in the dilution 1:100 (60 minu-
tes). Anti-Bak, anti-Bid and anti-Bad (all Abcam, 
Cambridge, UK) primary rabbit anti-human MoAbs 
were used in dilutions of 1:10 (60 minutes). Anti-
-Bcl-2 MoAb (DAKO, Glostrup, Denmark) was used 
at a concentration of 1:15; the time of incubation was 
30 minutes. Mouse anti-Mcl-1 MoAb (Abcam, Cam-
bridge, UK) was used at a concentration of 1:30 (30 
minutes). Rabbit anti-human FLIP antibody (Calbio-
chem-Novabiochem Corp., La Jolla, CA, USA) was 
used at a concentration of 1:30 (60 minutes). Mouse 
anti-human XIAP MoAb (Oncogene Res. Products, 
San Diego, CA,) was used in 1:100 dilution (incuba-
tion 60 minutes). MoAbs anti-Akt (Becton Dickinson, 
USA) and anti-Bcl-A1 (Abcam, Cambridge, UK) were 
used in concentrations of 1:15 and 1:30, respectively, 
for 30 minutes of incubation. All antibody dilutions 
were made in 1% PBS-BSA. All stainings were per-
formed at room temperature, in the dark. Increase or 
decrease in protein expression compared to the parallel 
control samples was defined as upregulation or down-
regulation, respectively.
Fluorescence measurements
All fluorescence measurements were performed by 
flow cytometry (FACScan; Becton-Dickinson, San 
Jose, CA, USA), using standard emission filters: green 
(l=530±20 nm; FL1), orange (l=560-600 nm; FL2) and 
red (l>600 nm; FL3), where necessary. Ten thousand 
cells per sample were calculated routinely in all expe-
riments.
Statistics
For calculation of the apoptotic index (AI) the per-
centage of Ann-V-positive cells was estimated. For the 
statistical analysis of data obtained, the range of the 
measured variable, mean, median and standard devia-
tion (SD) were calculated, using statistical software 
(STATISTICA v.7.0, Tulsa, OK, USA). The data are 
presented as mean ± SD values. The differences be-
tween values were evaluated with the non-parametric 
Mann-Whitney test, where the distribution of data 
was normal. The correlation between features was eva-
luated using the Spearman rank coefficient r. P values 
less than 0.05 were considered statistically significant.
results
Cytotoxic effect of AVA on CLL
In the preliminary experiments AVA was tested in con-
centrations of 1-50 μg/ml, in 24 and 48 hour cultures. 
For further studies 40 μg/ml of AVA and 48-hour in-
cubation were chosen as a minimal dose inducing si-
gnificant increase in cytotoxicity compared to the pa-
rallel, untreated controls (Figure 1).
Addition of cross-linking Ig antibodies did not further 
increase AVA cytotoxicity in comparison with cells cul-
tured in standard conditions. Also simulation of CDC 
(addition of complement from either pooled controls 
or from examined patients) and ADCC (sample in-
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cubation with addition of control PBMCs) effects did 
not significantly potentiate cytotoxic AVA activity.
Influence of incubation with 40 μg/ml of AVA on VEGF 
levels and VEGFR expression on CLL cells was also in-
vestigated. There was a significant decrease in VEGF con-
centration in culture medium after incubation with AVA 
(p=0.002). In contrast, there were no statistically signifi-
cant changes in either VEGFR-1 or VEGFR-2 expres-
sion levels before and after incubation with the study drug 
(both p>0.05).
Effect of AVA on healthy lymphocytes
During the experiments no significant cytotoxicity aga-
inst healthy PBMCs was found. Namely, after 48 hours 
of incubation the median percentage of PI+ CLL cells 
was 25.0% (9.8-32.5%), whereas in samples with heal-
thy PBMCs the value was 9.1% (0.9-13.1%; vs. control; 
N.S.).
Assessment of proapoptotic activity of AVA
AVA-induced apoptosis was examined using two mar-
kers: phosphatidylserine externalization (Ann-V) and 
DNA fragmentation (TUNEL assay). The percentage 
of Ann-V+ cells significantly correlated with the TU-
NEL+ cell rate (r=0.93. p<0.0001). Therefore Ann-
-V assay was used in further experiments for apopto-
sis evaluation. The median percentage of Ann-V+ cells 
after 48-hour incubation was 22.5% (14.1-28.1%) (vs. 
control – p=0.019).
Mechanisms of proapoptotic activity of AVA
Caspase activation
After 48 hours of incubation with AVA at the dose of 
40 μg/ml significantly elevated caspase-3 and -9 ac-
tivation in comparison with control samples was fo-
und. Median percentages of cells with caspase activa-
tion were 23.4% (11.3-29.1%) vs. 11.3% (5.6-19.1%) 
in the control (p=0.022) and 19.7% (12.6-27.9%) vs. 
9.3% (6.3-15.9%) in the parallel control (p=0.009). Ca-
spase-8 activation did not increase significantly after 
AVA treatment; median 8.3% (3.1-11.8%) (p>0.05) 
(Figure 2A).
Mitochondrial potential
The drop of DYm after 48-hour incubation with AVA 
was distinctly higher than in parallel, untreated cultures. 
The median percentage of cells with a drop of DYm was 
20.7% (8.7- 27.1%) vs. 12.4% (3.1-19.8%) (Figure 2B).
Fig. 1.  Cytotoxicity of AVA, measured as a percentage of propidium iodide-positive cells (% of PI+). The lowest concentration inducing significant increase in cytotoxicity 
after 48 hours of incubation was 40µg/ml (vs. control - p=0.031) (marked in red). Mean values and standard deviations are presented113
Expression of apoptosis-regulating proteins
After 48-hour incubation with AVA a significant in-
crease in expression of Bax (p=0.031), Bad (p=0.014) 
and Akt-P (p=0.027) proteins was observed as well 
as a decrease in Mcl-1 expression (p=0.007) (Table 
1, Figure 3). The level of other examined proteins 
did not significantly change in response to treatment 
with AVA.
Activity of AVA in combination 
with other drugs
Cytotoxicity of drug combinations
After 48-hour incubation with AVA or RIT used as 
a single drug, the median percentage of PI+ cells was 
25.0% and 21.3%, respectively (Table 2). The median 
rate of PI+ cells in samples treated with AVA+RIT 
combination was 38.7% and was significantly higher 
than with AVA or RIT used separately (p=0.037 and 
p=0.041, respectively).
ALT used as a single drug induced a median percen-
tage of PI+ cells of 27.3%. Combination of AVA and 
ALT exerted increased cytotoxicity (median percen-
tage of PI+ cells 50.5%), significantly higher than 
AVA or ALT alone (p=0.008 and p=0.001, respec-
tively).
113
Fig. 2.  Caspase activation (A) and drop of mitochondrial potential (B) after 48 hours of incubation with AVA. Percentages of cells with caspase activation or drop of mito-
chondrial potential were shown on Y axis. Mean values and standard deviations are presented
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Cytotoxicity of PNA: 2-CdA and FA alone and in combi-
nations with AVA. After 48 hours of incubation in samples 
treated with AVA or 2-CdA alone the median percentage 
of PI+ cells was 53.4%. The median percentage of PI+ cells 
after treatment with AVA+2-CdA was 64.8% and was si-
gnificantly higher only in comparison to the effect of AVA 
(p<0.001) (AVA+2-CdA vs. 2-CdA - N.S.). After 48 hours 
of incubation with FA alone the percentage of PI+ cells was 
46.1%. The median percentage of PI+ cells after AVA+FA 
treatment was 67.3%, and, similarly to 2-CdA, was signifi-
cantly higher only in comparison to the effect of AVA alo-
ne (p<0.001) (AVA+FA vs. 2-CdA - N.S.).
After incubation with MAF alone the median percen-
tage of PI+ cells was 38.1%. In samples treated with 
the combination AVA+MAF it was 52.2% and did not 
differ from the effect of MAF (N.S.), but was higher 
than after treatment with MAF alone (p=0.010).
Treatment with RAPA used as a single drug induced a me-
dian of 36.8% of PI+ cells. The median rate of cytotoxicity 
in response to AVA+RAPA was 60.3%, and was significan-
tly higher when compared with the effect of both AVA and 
RAPA used as single drugs (p=0.034 and p=0.006, respec-
tively).
Fig. 3.  Expression of apoptosis-regulating proteins after 48 hours incubation with AVA + RIT (A), AVA + ALT (B) and AVA + RAPA (C). On Y axis n-fold proportions of mean 
fluorescence cytotoxicity (MFI) between cell treated with the study drugs and untreated, control samples. Proteins with significant increase or decrease in expression 
are marked in red
Table 1. Expression of apoptosis-regulating proteins after 48 hours of incubation with AVA
Protein
Control AVA
Median MFI* (range) N** p=
Bax 81.2 (41.4-167.3) 151.2 (67.2-211.8) 1.86 0.031
Bid 116.2 (50.5-176.3) 131.9 (30.2-209.5) 1.14 N.S.
Bak 75.2 (29.7-130.9) 85.7 (34.6-163.4) 1.14 N.S.
Bad 99.5 (32.1-158.6) 190.1 (49.2-269.3) 1.91 0.014
Bcl-2 204.9 (70.4-391.2) 179.9 (65.0-281.3) 0.88 N.S.
Mcl-1 165.1 (51.6-270.5) 75.1 (20.0-141.7) 0.45 0.007
XIAP  127.3 (40.1-190.6) 147.3 (32.5-206.7) 1.16 N.S.
FLIP  131.9 (51.7-211.1) 150.1 (37.7-202.1) 1.14 N.S.
Bcl-2-A1  98.3 (54.9-174.9) 58.3 (20.3-197.8) 0.59 N.S.
Akt-P 174.5 (44.7-271.3) 64.5 (29.0-169.2) 0.37 0.001
* MFI - mean fluorescence intensity
** N - proportion of protein expression (MFI) in examined sample vs. control
N.S. – not significant115
Changes in apoptosis-regulating protein 
expression in response to combined 
treatment
Expression of apoptosis-regulating proteins was exami-
ned in samples treated with AVA in combinations with 
other drugs. Results of effects on protein expression are 
presented here only for drug combinations which exer-
ted significantly higher cytotoxicity than single agents. As 
mentioned, such effective combinations were AVA+RIT, 
AVA+ALT and AVA+RAPA.
In samples incubated with AVA+RIT there was a signi-
ficant elevation of Bax (p<0.040) and Bak (p<0.018) and 
decrease in Bcl-2 (p<0.027) and Mcl-2 (p<0.025) protein 
expression (Figure 3A).
The AVA+ALT combination triggered overexpression 
of Bak (p<0.030) and Akt-P (p<0.003) as well as Mcl-1 
(p<0.017) and XIAP (p<0.007) downregulation (Figure 
3B).
In samples cultured with AVA+RAPA significant ele-
vation of Bax (p<0.037), Bad (<0.001) and Akt-P 
(p<0.001) was observed as well as decrease in Mcl-1 
(p<0.030) and XIAP (p<0.006) protein expression (Fi-
gure 3C).
dIscussIon
The crucial role of neoangiogenesis in survival of neo-
plastic infiltration has been proved for many solid tu-
mors. However, this process probably plays a role also 
in pathogenesis of hematological malignancies, inclu-
ding acute leukemias [28, 29, 30].
Several studies have indicated the importance of neo-
angiogenesis in CLL. Namely, Molica et al. [17] found 
that increased serum VEGF levels can be predictors of 
risk of CLL progression. VEGFR-1, VEGFR-2 and 
VEGFR-3 are the high-affinity receptors of mVEGF, 
which play an important role in de novo blood vessel 
formation and hematopoietic cell development. All of 
them are expressed on CLL cells [3]. A correlation be-
tween VEGFR-2 expression and patient survival was 
reported in CLL [7]. Moreover, Gora-Tybor et al. [12] 
found a strong, positive correlation between the serum 
level of VEGF and VEGFR-2 in CLL. VEGFR-2, 
but not VEGF R1, also correlated with lymphocyte 
count and clinical course. It was shown that VEGF/
VEGFR2 interaction down-regulates matrix metallo-
proteinase-9 through STAT1 activation and inhibits 
CLL cell migration [25]. Moreover, circulating endo-
thelial cells were reported as a noninvasive marker of 
angiogenesis in patients with CLL [13]. Altogether, 
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Table. 2. Cytotoxicity of AVA in combinations with other drugs. Cytotoxicity was measured as a percentage of propidium iodide-positive cells (% PI+). Data obtained 
after 48 hours of incubation are presented
Drugs/combinations % of PI+ cells Statistics (p=)
AVA alone 25.0 (9.8-32.5)
RIT alone 19.2 (7.6-25.5)
AVA + RIT 38.7 (9.3-52.4) vs. AVA - 0.041, vs. RIT  - 0.037
ALT alone 27.3 (11.3-38.7)
AVA + ALT 50.5 (17.4-72.5) vs. AVA - 0.008, vs. ALT - 0.001
2-CdA alone 53.4 (17.2-77.9)
AVA + 2-CdA 64.8 (25.6-80.1) vs. AVA - <0.001, vs. 2-CdA – N.S.
FA alone 46.1 (22.7-75.5)
AVA + FA 67.3 (19.4-84.2) vs. AVA - <0.001, vs. FA - N.S.
MAF alone 38.1 (15.8-59.3)
AVA + MAF 52.2 (24.9-75.3) vs. AVA - 0.010, vs. MAF - N.S.
RAPA alone 36.8% (18.9–71)
AVA + RAPA 60.3% (45.1–98.3) vs. AVA - 0.006, vs. RAPA - 0.034
AVA – bevazicumab. RIT – rituximab. ALT – alemtuzumab. 2-CdA – cladribine. FA -  fludarabine. MAF – mafosfamide. RAPA - rapamycin
N.S. – not significant
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these observations suggest that neoangiogenesis may 
have an important role in CLL development and pro-
gression.
AVA is a MoAb with antiangiogenic capacity, appro-
ved for treatment of solid tumors. The drug showed 
high anti-tumor activity of AVA in combinations with 
routine cytostatics in colon [11], breast [6], lung [4], 
and pancreatic [15] cancers. So far, there are only a few 
reports concerning the use of AVA in hematologic ma-
lignancies. A promising phase II study with AVA as a 
single drug was performed in 52 relapsed patients with 
aggressive non-Hodgkin lymphomas, including diffuse 
large B-cell or mantle cell lymphoma [22]. Moreover, 
the RIT, AVA and CHOP regimen (RA-CHOP) in 
untreated diffuse large B-cell lymphoma patients sho-
wed high activity and good tolerability in early clinical 
studies [8]. However, the further phase III study with 
RA-CHOP was finally stopped because of unaccepta-
ble side effects.
In CLL, only a phase II study was performed in 13 pa-
tients, showing weak activity of AVA used alone [21]. 
However, exact effects of antiangiogenic treatment, inc-
luding AVA activity, have been poorly explored in this di-
sease so far.
In this study we found significant cytotoxicity of 
AVA against ex vivo CLL cells in a dose of 40 μg/ml, 
after 48 hours of incubation. Importantly, AVA did 
not influence survival of normal lymphocytes from 
healthy donors.
AVA specifically binds VEGF, thus decreasing its level in 
serum or culture medium, which was observed in our in 
vitro experiments. AVA limits accessibility of VEGF to 
its receptors [27]. In fact, we did not find any effects of 
AVA on VEGFR-1 and VEGFR-2 expression.
AVA, similarly to other IgG1 monoclonal antibodies, 
has potential to bind Fcγ receptors and complement 
elements. However, in our studies cytotoxicity of AVA 
was independent from CDC or ADCC mechani-
sms. This was in concordance with the observations of 
Wang et al. [26] on AVA in in vitro cell lines Calu-6, 
DLD-1 and WIL2-S.
Our study is the first to show that the main mechanism 
of the cytotoxic effect on CLL cells is apoptosis, which 
was confirmed by both Ann-V and TUNEL assays. The 
drug triggered activation of caspase-3 and -9, with no 
significant changes in caspase-8 activity. Moreover, AVA 
caused a distinct drop of DYm in CLL cells. Thus, AVA-
-induced apoptosis of CLL is triggered through the mi-
tochondrial, but not the receptor pathway of caspase ac-
tivation.
VEGF is known to bind to its receptors and trigger a 
signal transduction cascade, which leads to prolifera-
tion [1] and migration [1, 2, 20] of vascular endothelial 
Fig. 4.  Proposed mechanism of AVA action in CLL cells. Block of VEGF availability for its receptors (VEGFRs) leads to overexpression of Bak and Bad with downregulation 
of Mcl-1 and Akt proteins. This, in turn, activates mitochondrial pathway of apoptosis, with caspase-9 and -3 activation, DNA fragmentation and programmed 
cell death117
was used in this study as a biologically active metaboli-
te of cyclophosphamide in in vivo conditions, which also 
shows in vitro activity. Additionally, RAPA was tested 
as a member of the promising mTOR kinase inhibitors, 
agents with antiproliferative and cell migration-inhibi-
ting effects and high antitumor potential. Combination 
of AVA with RIT, ALT or RAPA significantly increased 
cytotoxicity compared with these drugs used separately. 
A similar tendency was observed for combinations with 
2-CdA or FA, but the differences were not statistically 
significant.
In conclusion, this is the first study to show that AVA has 
selective cytotoxic potential against CLL cells, inducing 
apoptosis through the mitochondrial pathway of caspa-
se activation, with no influence on healthy lymphocytes. 
Lack of VEGF receptor inhibition due to AVA-induced 
neutralization of VEGF triggers overexpression of Bak 
and Bad, with downregulation of Mcl-1 and Akt prote-
ins. Simultaneous incubation with AVA and RIT, ALT 
or RAPA potentiates efficacy of particular drugs used as 
single agents. Thus, such combined treatment may be a 
promising therapeutic strategy; further studies for confir-
mation of these results are warranted.
cells. A possible mechanism of this activity is induction 
of the inhibitor of antiapoptotic survivin and XIAP, from 
the apoptosis protein (IAP) family [24]. VEGF acts as 
an apoptosis inhibitor via activation of Akt kinase [10], 
within the PI3K (phosphatidylinositol 3-kinase) signal 
transduction pathway [23]. Finally, VEGF increases 
expression of antiapoptotic proteins Bcl-2 and Bcl-2-A1 
in endothelial cells [9]. AVA, by binding VEGF, inhibits 
the intracellular transduction pathway, thus activating 
apoptosis of endothelial cells.
As mentioned, so far there have been no reports on me-
chanisms of AVA activity in CLL cells. We found that 
48-hour incubation with AVA induced changes in expres-
sion of several apoptosis-regulating proteins, with overe-
xpression of Bak, Bad and Akt and downregulation of 
Mcl-1 and Akt. Taking these data together with know-
ledge on AVA activity in endothelial cells, we propose po-
ssible mechanisms of its cytotoxicity in CLL cells. A sim-
plified scheme is shown in Figure 4.
To our best knowledge our study is the first to address 
cytotoxicity of AVA in combination with drugs already 
used in CLL – RIT, ALT, PNA and MAF. The latter drug 
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